All In Biotech

Drug Trial Radar · NCT05697614

The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children

The Efficacy and Safety of First-Line Anti-Epileptic Drugs (AEDs) as Substitution Therapy in Children Who Are Resistant to Second-Line AEDs

Last checked: Nov 19, 2026Latest source record: Jan 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 1, 2023

Primary completion

May 30, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Dr Cipto Mangunkusumo General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional study is to learn about the efficacy and safety of first line anti epileptic drugs (AEDs) as substitution therapy for children who are resistant to second-line AEDs. The main question to answer it aims are : how much the difference proportion of responders (responders are children who achieve the decrease of seizure frequencies by 50%) how much time it is needed to achieve the decrease of seizure frequencies by 50% The patients who are eligible for the study and have given their consent, will be enrolled, divided into 2 groups, the control and intervention. The participant should follow the 14 weeks of intervention that consists of 6 phases : baseline, initial dose, titration dose, maintenance dose, tapering-off dose, and new combination maintenance dose.

Conditions

  • Drug Resistant Epilepsy

Interventions

  • Valproic acidDrug

    valproic acid is used for general epilepsy type, used in experimental group

  • CarbamazepinDrug

    carbamazepine is used for focal type epilepsy, used in experimental group

  • PhenytoinDrug

    phenytoin is used for both general or focal epilepsy in case valproic acid or carbamazepine is contraindicated, used in experimental group

  • LamotrigineDrug

    lamotrigine is used for general epilepsy type, used in control group

  • ClobazamDrug

    clobazam is used for both general or focal epilepsy in case if lamotrigine or oxcarbazepine is not possible to be administered and is used particularly in myoclonic jerk , used in control group

  • OxcarbazepineDrug

    oxcarbazepine is used for focal type epilepsy, used in control group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the different proportion of responders between groups who get first-line anti-epileptic drugs (intervention) and second-line anti-epileptic drugs (control)Time frame: trough the study completion, about 14 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Harapan Kita Hospital

    Jakarta, Indonesia · Recruiting

  • Fatmawati Hospital

    Jakarta, Indonesia · Recruiting

  • Cipto Mangunkusumo Hospital

    Jakarta Pusat, Jakarta Special Capital Region, Indonesia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.